LON:NCYT

Novacyt Share Forecast, Price & News

GBX 401.50
-8.50 (-2.07 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
395.68
Now: GBX 401.50
417.37
50-Day Range
406.90
MA: GBX 663.67
755
52-Week Range
202.75
Now: GBX 401.50
1,276
Volume991,841 shs
Average Volume839,891 shs
Market Capitalization£283.56 million
P/E Ratio7.75
Dividend YieldN/A
BetaN/A
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone33 1 39 46 51 04
Employees110
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£78.23 million
Cash FlowGBX 30 per share
Book ValueGBX 89.40 per share

Profitability

Miscellaneous

Market Cap£283.56 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

See More Headlines

MarketRank

Overall MarketRank

0.63 out of 5 stars

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
GBX 401.50
-8.50 (-2.07 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novacyt (LON:NCYT) Frequently Asked Questions

Is Novacyt a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novacyt in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novacyt stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NCYT, but not buy additional shares or sell existing shares.
View analyst ratings for Novacyt
or view top-rated stocks.

What stocks does MarketBeat like better than Novacyt?

Wall Street analysts have given Novacyt a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novacyt wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Novacyt's stock price been impacted by Coronavirus?

Novacyt's stock was trading at GBX 107.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NCYT shares have increased by 273.5% and is now trading at GBX 401.50.
View which stocks have been most impacted by COVID-19
.

Who are Novacyt's key executives?

Novacyt's management team includes the following people:
  • Mr. Graham Mullis, CEO & Director (Age 58)
  • Mr. Anthony Dyer, Chief Corp. Devel. Officer, Company Sec. & Director
  • Mr. James Martin McCarthy, CFO & Director (Age 55)
  • Ms. Lisa Henriet, Group Operations Director
  • Ms. Mandy Cowling, Corp. & Investor Relations Mang.
  • Ms. Wendy Karban, Group HR Mang.
  • Mr. Paul Eros, Chief Bus. Officer
  • Mr. Guillermo Raimondo, Chief Commercial Officer
  • Mr. Gérald Ulrich, Chief Exec. Officer of Bus. Devel.
  • Mr. Steve Gibson, Group Financial Controller

Who are some of Novacyt's key competitors?

What other stocks do shareholders of Novacyt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Biocept (BIOC), Ecolab (ECL), genedrive (GDR), Geron (GERN), Immunic (IMUX), Tiziana Life Sciences (TILS), Verastem (VSTM), VYNE Therapeutics (VYNE), Antero Midstream (AM) and Aileron Therapeutics (ALRN).

What is Novacyt's stock symbol?

Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT."

How do I buy shares of Novacyt?

Shares of NCYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Novacyt's stock price today?

One share of NCYT stock can currently be purchased for approximately GBX 401.50.

How much money does Novacyt make?

Novacyt has a market capitalization of £283.56 million and generates £78.23 million in revenue each year.

How many employees does Novacyt have?

Novacyt employs 110 workers across the globe.

What is Novacyt's official website?

The official website for Novacyt is www.novacyt.com.

How can I contact Novacyt?

The company can be reached via phone at 33 1 39 46 51 04.


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.